ライフサイエンスコーパス: loratadine

1 es) obtained from rats orally dosed with 14C-loratadine.

2 complex bioactive molecules sclareolide and loratadine.

3 proach, we have used the antihistamine agent loratadine (1).

4 Oral loratadine (10 mg/kg/d) maintained survival, inhibited i

5 Finally, loratadine (10 microM) failed to inhibit HERG K+ channel

6 ed on several metabolites and derivatives of loratadine (a long-acting and nonsedating tricyclic anti

7 Loratadine, a clinically used histamine H1 receptor anta

8 A series of loratadine analogues were synthesized to gain insight in

9 nd simvastatin (relative risk or RR = 1.69); loratadine and alprazolam (RR = 1.86); loratadine and du

10 .69); loratadine and alprazolam (RR = 1.86); loratadine and duloxetine (RR = 1.94); loratadine and ro

11 of LC/MS/MS methods for the quantitation of loratadine and its metabolite, descarboethoxyloratadine,

12 In the present study, two commercial drugs, Loratadine and Miconazole, were identified as potential

13 show that rigidifying the core structure of loratadine and related analogues through N-oxidation aff

14 .86); loratadine and duloxetine (RR = 1.94); loratadine and ropinirole (RR = 3.21); and promethazine

15 ntified with their p-values less than 1E-06: loratadine and simvastatin (relative risk or RR = 1.69);

16 itro drug metabolism and inhibition potency, loratadine and simvastatin and tegaserod and promethazin

17 dation in two venerable drug-like scaffolds, Loratadine and Varenicline, show the likely generality o

18 es of the conformationally dynamic Claritin (loratadine) and Clarinex (desloratadine) scaffolds have

19 were treated orally with the H1R antagonist, loratadine, and/or the H4R antagonist, JNJ7777120.

20 We identified loratadine as the safest representative antihistamine fo

21 patch-clamp electrophysiology, we found that loratadine blocked Kv1.5 current measured from inside-ou

22 Loratadine did not alter the kinetics of Kv1.5 current a

23 alicylate, caffeine, l-leucine, l-histidine, loratadine, ibuprofen, acetaminophen, acetylsalicylic ac

24 Treatment with montelukast and loratadine inhibited the release of cysteinyl leukotrien

25 Loratadine inhibited toxin B-induced MIP-1alpha secretio

26 eg, cetirizine, fexofenadine, desloratadine, loratadine), intranasal antihistamines (eg, azelastine,

27 It is concluded that loratadine is an effective blocker of Kv1.5 that interac

28 Loratadine (LoR) is a highly lipophilic and practically

29 Loratadine may be repurposed to optimize existing therap

30 the effects of the nonsedating antihistamine loratadine on a rapidly activating delayed-rectifier K+

31 Treatment with loratadine or JNJ7777120 individually partially suppress

32 ene antagonist montelukast and antihistamine loratadine or two matched placebos were administered for

33 eg, cetirizine, fexofenadine, desloratadine, loratadine) or an intranasal antihistamine (eg, azelasti

34 gram amounts of the pharmaceutical compounds loratadine, oxycodone, and atenolol deposited on glass,

35 eceptor antagonists such as diphenhydramine, loratadine, ranitidine, and cimetidine, but has modest a

36 Oral loratadine suppressed human MIP-1alpha expression in mon

37 This interaction suggests a potential for loratadine to alter cardiac excitability in vivo.

38 Splenocytes from loratadine-treated mice conferred anti-inflammatory effe

39 This effect of loratadine was achieved by a reduced number of openings

40 the single-channel level, the main effect of loratadine was to reduce the mean probability of opening

41 Twenty-six analogues of loratadine were isolated and fully characterized by NMR.